Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active *Mycobacterium tuberculosis*: a retrospective study

Tomonori Hirashima1*, Yoshitaka Tamura2, Yuki Han3, Shoji Hashimoto3, Ayako Tanaka1, Takayuki Shiroyama1, Naoko Morishita1, Hidekazu Suzuki1, Norio Okamoto1, Shinobu Akada4, Makoto Fujishima5, Yoshihisa Kadota6, Kazuya Sakata1, Akiko Nishitani7, Satoru Miyazaki7 and Takayuki Nagai3

Abstract

**Background:** In our previous study, colorectal cancer (CRC) patients with active *Mycobacterium tuberculosis* (**MTB**) tolerated concurrent anti-cancer chemotherapy (anti-CCT) and anti-MTB chemotherapy. In this study, we retrospectively confirmed the efficacy and safety of concurrent chemotherapy in a greater number of patients with different types of malignancies.

**Methods:** We enrolled 30 patients who were treated concurrently with anti-CCT and anti-MTB regimens between January 2006 and February 2016. Cancer and MTB treatments were administered according to the approved guidelines.

**Results:** Patient demographics included: men/woman: 24/6; median age: 66.5 years; Eastern Cooperative Oncology Group performance status 0–1/2–4: 24/4/2; Stage IIb–IIIC/IV/recurrence: 6/22/2; lung cancer (LC)/CRC/other: 15/10/5; and MTB diagnosis (before or during anti-CCT): 20/10 (LC: 8/7; CRC: 8/2; other: 4/1). For anti-CCT, 23 patients received two cytotoxic agents with or without targeted agents and 7 patients received a single cytotoxic or targeted agent. The overall response rate was 36.7%. Regarding anti-MTB chemotherapy, 22 patients received a daily drug combination containing isoniazid, rifampicin, and ethambutol, plus pyrazinamide in 15 of the 22 patients, followed by daily isoniazid and rifampicin; the remaining 8 patients received other combinations. Hematological adverse events of Grade ≥3 were observed in 19 (67.9%) of 28 patients; laboratory data were lost for the remaining 2. Grade 3 lymphopenia and higher were significantly more frequent in LC compared to other malignancies (**P** < 0.005). Non-hematological adverse events of Grade ≥3 were observed in 5 (16.7%) of 30 patients. One CRC patient experienced Grade 3 hematopoeisis and another 2 experienced Grade 3 anaphylaxis. One patient with cholangiocellular carcinoma and gastric cancer experienced Grade 3 pseudomembranous colitis as a result of a *Clostridium difficile* infection. One patient (3.3%) died of pemetrexed-induced pneumonitis. The success of the anti-MTB chemotherapy was 70.0%. There were no MTB-related treatment failures. The median overall survival (months, **95.0% confidence interval**) was 10.5 (8.7–36.7), 8.7 (4.7–10.0), 36.7 (minimum 2.2), and 14.4 (minimum 9.6) for all patients combined, LC, CRC, and Other malignancies, respectively. LC patients experienced delayed MTB diagnosis and shorter overall survival.

(Continued on next page)
Background

*Mycobacterium tuberculosis* (MTB) represents the leading cause of death from an infectious disease worldwide [1], with the majority of cases occurring in Asia (61.0%) and Africa (26.0%). Incidence and mortality rates are noticeably higher in Japan than other developed countries [1].

Although active MTB infections may be present in cancer patients, our previous preliminary report [2] is the only study to discuss the clinical course and chemotherapy outcomes of concurrent anti-cancer chemotherapy (anti-CCT) and anti-MTB chemotherapy, revealing that patients with metastatic colorectal cancer (CRC) and active MTB could safely and effectively continue anti-CCT, and achieve comparable survival to those without the infection, upon receiving appropriate MTB treatment [2].

In this study, we retrospectively examined the clinical course and chemotherapy outcomes of a larger number of patients treated concurrently with anti-CCT and anti-MTB chemotherapy.

Methods

Study approval

The present retrospective study was approved by the Institutional Review Board (IRB) of the Osaka Habikino Medical center on 30 January 2017 (approval number: 808–1). The board waived the requirement for informed written consent due to the anonymous nature of the data, and no risk of exposure to subjects.

Patient selection

We enrolled 30 cancer patients with active MTB who were treated concurrently with anti-CCT and anti-MTB chemotherapy at our institution between January 1, 2006 and February 29, 2016. The 6 metastatic CRC patients with active MTB from our previous study [2] were also included.

Clinical review

As described previously, [2] the clinical history of eligible patients was retrospectively reviewed. We collected baseline demographic data and anti-CCT data, which were also collected from clinical records or pharmacy database. Complete history and physical examinations; surgical reports; findings of flexible bronchoscopy, colonoscopy, and esophagastroduodenoscopy; imaging investigations; pathological reports, and blood test results were available for all patients at the time of anti-MTB chemotherapy.

Conclusions: Concurrent chemotherapy is effective and safe for treating cancer patients with active MTB.

Keywords: Concurrent chemotherapy, Tuberculosis, Breast cancer, Colorectal cancer, Efficacy, Gastric cancer, Lung cancer, Safety

MTB diagnosis

As described previously [2], MTB diagnosis was performed by smears and cultures of various patients’ specimens or chest computed tomography (CT) image in patients without microbiological evaluation. The method of choice for confirming MTB infection was Ziehl-Neelsen staining of sputum smear samples [3]. Polymerase chain reaction (PCR) or loop-mediated isothermal amplification (LAMP) [4] was performed for patients with positive sputum smears to distinguish MTB from other mycobacteria. If the sputum smears were negative or specimens other than sputum were obtained, the diagnosis of MTB was confirmed by culturing mycobacterial organisms. Drug sensitivity was determined for all cases with positive culture. Liquid media with the Mycobacteria Growth Indicator Tube (MGIT) [5] and solid media with the Ogawa-Kudoh method [6] were both used for culturing mycobacteria. Drug sensitivity was determined for all cases. Quantitative drug susceptibility testing for MTB was performed using the MTB-I® (Kyokuto Pharmaceutical Industrial Co., Ltd., Tokyo, Japan) modified Minimum Inhibitory Concentration method [7].

Treatment of MTB infection

As described previously [2], in cancer patients with active MTB, appropriate anti-MTB agents were administered for approximately 1.5 months prior to anti-CCT, according to the American Thoracic Society and Infectious Diseases Society of America guidelines [8] A multi-drug resistant MTB, based on the sensitivity test, negated the initiation of anti-CCT. Since MTB patients with severe complications often require longer courses of treatment than those without such complications, patients treated with anti-CCT also received long-term treatment for MTB. Thus, the patients received 2 months of isoniazid (H), rifampicin (R), ethambutol (E), and pyrazinamide (Z), followed by HR for 7 months, or 6 months of HRE, followed by HR for 6 months as standard anti-MTB chemotherapy. The majority of patients who could not be treated with standard anti-MTB chemotherapy, due to side effects or drug resistance, were treated with a levofloxacin (X)-based regimen.

Follow-up MTB culture

After commencing anti-MTB chemotherapy, sputum specimens were cultured every other week for the first...
3 months. Once two consecutive sputum cultures were negative, cultures were done monthly until the course of MTB treatment was completed.

**Definition of MTB treatment outcomes**

MTB treatment outcomes were based on the World Health Organization’s definitions [9]. Treatment success included “cure” and “treatment completed”. A “cured” patient was defined as one who had completed the planned treatment and had two consecutive negative cultures. Patients with treatment failure had positive cultures ≥5 months into MTB treatment.

**Cancer staging and treatment**

Cancer staging and treatment were performed according to the guidelines of the respective lung cancer (LC) [10], CRC [11], gastric cancer (GC) [12], breast cancer, [13], and cholangiocellular carcinoma (CCA) [14] societies.

The policy of our institution was to commence anti-CCT immediately if patients were sensitive to anti-MTB agents. However, if patients were resistant or had experienced intolerable side effects while awaiting sensitivity test, anti-CCT was suspended until a decision could be reached concerning the appropriate drug combination and duration of anti-MTB chemotherapy. Additionally, when MTB cultures could not be obtained, due to a number of reasons, or the physician could not await the results of the sensitivity test due to rapid tumor progression, anti-CCT was commenced, following informed patient consent.

**Assessment of anti-cancer chemotherapy outcomes**

Patients’ best response to chemotherapy was collected from the records of weekly meetings at our institution and clinical summaries. Based on the Response Evaluation Criteria in Solid Tumors [15], the responses of tumors to cytotoxic agents were categorized as complete or partial responses and stable or progressive disease. Tumor responses that could not be assessed were recorded as “not evaluable”. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0 [16].

**Statistical analyses**

Overall survival (OS) was measured from the date of commencing concurrent chemotherapy (for both cancer and MTB) to the date of death or last follow-up (February 28, 2017). OS rates were estimated using the Kaplan-Meier method [17]. The duration of concurrent chemotherapy was defined as the time from commencing concurrent chemotherapy to the end date. All statistical analyses were conducted using R statistical software (version 3.2.0). Patient background data were analyzed using chi-square and Fisher’s exact test for categorical variables. A P < 0.05 was considered statistically significant.

**Results**

**Patient demographics**

In total, 30 cancer patients with active MTB who were treated concurrently with anti-CCT and anti-MTB chemotherapy between January 1, 2006 and February 29, 2016 at our institution, were enrolled in this study. Fifteen patients were diagnosed with LC (non-small cell LC [NSCLC, n = 10] and small cell LC [SCLC, n = 5]), 10 patients were diagnosed with CRC (rectal cancer [n = 7], sigmoid cancer [n = 2], and transverse colon cancer [n = 1]), and 5 patients were diagnosed with other malignancies (GC [n = 1], Breast Cancer [n = 1], LC with GC [n = 1], CRC with GC [n = 1], and CCA with GC [n = 1]). The patient demographics are summarized in Table 1. No significant differences in patient demographics were observed among LC, CRC, and other malignancy groups. However, LC patients tended to be more frequently diagnosed with active MTB during anti-CCT in comparison to those with CRC or other malignancy.

**Chest CT imaging**

Thoracic CT findings at the time of MTB diagnosis is presented in Fig. 1 (a-d). These CT images present a combination of thick and thin walled lung cavities, infiltration shadows, and multiple nodules. There were no consistent findings on CT imaging based on the type of malignancy.

**Bacteriological examinations**

The findings of bacteriological examinations are summarized in Table 2. Twenty (66.7%) patients had MTB-positive sputum smears. In 25 (83.3%) cultures were positive for MTB and negative cultures were reported in 5 (16.7%). Cultures were negative for MTB in 3 LC and 2 CRC patients. In the former, active MTB was diagnosed by PCR of sputum in 2 cases and LAMP of sputum in 1, alongside CT results, while in the latter, the diagnosis was confirmed by PCR of sputum in one, and the results of the CT scan and clinical course in the other. In the 25 cases positive for MTB, 22 (88.0%) were sensitive, 2 (8.0%) were resistant (one MTB strain was resistant to H and streptomycin, another to H and Z), and 1 (4.0%) was not tested for sensitivity because of concomitant Nontuberculous Mycobacteriosis. In 2 of 25 patients with MTB-positive cultures, the time to MTB-positive culture could not be confirmed because the culture specimens were obtained in other institutes. Therefore, the time to MTB-positive culture in 23 patients was demonstrated by MGIT (n = 18) and Ogawa-Kudoh method (n = 5). The time (days: mean ± SD) to MTB-positive cultures was significantly shorter.
for MGIT than for the Ogawa-Kudoh method (16.2 ± 8.7 vs 37.6 ± 8.4; \( P < 0.0005 \)). Furthermore, the time (days: mean ± SD) to sensitivity testing in 22 patients except one with concomitant *Nontuberculous Mycobacteriosi* was 12.6 ± 3.5.

**MTB treatment until concurrent chemotherapy**

Of the 30 patients enrolled in this study, 4 received X-based regimen from the start of *MTB* treatment due to resistant to INH (\( n = 2 \)), past history of RFP-induced systemic eruption (\( n = 1 \)), and preventing the drug interaction between Paclitaxel and RFP via CYP3A4 and CYP2C8 (\( n = 1 \)). Subsequently, 8 patients received concurrently X-based regimens and anti-CCT. The remaining 22 patients received concurrent HREZ or HRE and anti-CCT as planned, without many adverse events except in one patient who experienced a paradoxical response on day 23 after starting HREZ and was kept on HREZ while taking prednisolone. Thus, until concurrent chemotherapy, 6 (20.0%) of the 30 patients experienced adverse events with *MTB* treatment alone, and in 5 the planned *MTB* treatment was changed to other regimens.

**Outcomes of concurrent chemotherapy**

Details of the initial concurrent anti-CCT regimens are listed in Table 3. Twenty-three patients (76.7%) received intensive anti-CCT regimens with or without targeted agents, 5 patients (16.7%) received a single cytotoxic agent, and 2 patients (6.7%) received a single targeted agent. The overall response rates (ORRs) were 36.7, 33.3

| Table 1 Patient Characteristics | Patients |
|-------------------------------|----------|
| Characteristic                | All (n = 30) | LC (n = 15) | CRC (n = 10) | Other (n = 5) |
|-------------------------------|-------------|-------------|-------------|--------------|
| Sex, n (%)                    | M 24 (80.0) | 12 (80.0) | 8 (80.0) | 4 (80.0) |
| Age (years), median (range)   | 66.5 (39–79) | 68.0 (43–79) | 62.5 (43–75) | 56.0 (39–75) |
| ECOG PS, n (%)                | 0–1 24 (80.0) | 12 (80.0) | 8 (80.0) | 4 (80.0) |
| Stage, n (%)                  | IIIB-III A 3 (10.0) | 2 (13.3) | 0 (0.0) | 1 (20.0) |
| Postoperative recurrence, n (%) | 2 (6.7) | 1 (6.7) | 1 (10.0) | 0 (0.0) |
| Line of cancer chemotherapy at the commencement of concurrent chemotherapy, n (%) | Adjuvant 1 (3.3) | 0 (0.0) | 0 (0.0) | 1 (20.0) |
| Diabetes mellitus, n (%)      | Y 7 (20.7) | 3 (20.0) | 2 (20.0) | 2 (40.0) |
| MTB diagnosis, n (%)          | Before anti-CCT 20 (66.7) | 8 (53.3) | 8 (80.0) | 4 (80.0) |
| During anti-CCT               | 10 (33.3) | 7 (46.7) | 2 (20.0) | 1 (20.0) |

Abbreviations: CCT cancer chemotherapy, CRC colorectal cancer, ECOG Eastern Cooperative Oncology Group, F female, LC lung cancer, M male, MTB Mycobacterium tuberculosis, N no, PS performance status, Y yes
40.0, and 40.0% for all patients combined, LC patients, CRC patients, and patients with other malignancies, respectively. In 15 LC patients, all 5 patients with SCLC received intensive cytotoxic treatment (carboplatin plus etoposide) as first line chemotherapy (Table 3) with a high response rate (80%). Of 10 NSCLC patients, 4 (40%) received platinum doublets as intensive first regimen, and one of them achieved partial response. In the remaining 6 patients (60%), one received platinum doublets, three were administered single cytotoxic agent, and two received erlotinib as re-challenge regimen. They received those regimens as second-line or later anti-CTT and there was no responder.

The main anti-MTB regimens were as follows: HREZ/HR (n = 15 patients; LC [n = 8], CRC [n = 4], other [n = 3]); HRE/HR (n = 7 patients; LC [n = 2], CRC [n = 4], other [n = 1]); and X-based (n = 8 patients; LC [n = 5], and CRC [n = 2], other [n = 1]). The median duration (range) of MTB treatment was 275.0 (72–637), 274.0 (90–469), 259.0 (72–539), and 368.0 (273–637) days for all patients combined, those with LC, CRC, and other malignancies, respectively. The success of anti-MTB chemotherapy in each of the above groups was 70.0, 66.7, 70.0, and 80.0%, respectively. There were no MTB-related treatment failures. The median duration (range) of concurrent chemotherapy was 157.5 (13–408), 117.0 (20–245), 168.5 (13–408), and 155.0 (51–376) days for all patients combined, those with LC, CRC, and other malignancies, respectively.

In 20 (66.7%) patients MTB was cured, one (3.3%) completed the course for MTB treatment, and 9 (30%) died while receiving MTB treatment. Among the 9 patients who died, one died of pemetrexed-induced pneumonitis and 8 died of cancer.

In 2 CRC patients with performance status of 3, anti-CCT was started because of patients’ insistence and after the approval of the Cancer Board. In one of these patients, MTB was resistant to H and Z. Hence, X + Streptomycin was administered, alongside Folnic acid, fluorouracil and irinotecan for 1 cycle. The patient died 54 days after treatment withdrawal. Regular MTB cultures performed every other week were negative for six consecutive times. The other patient received modified regimen of Folnic acid, fluorouracil and oxaliplatin for 4 cycles and died 57 days after treatment withdrawal.

Epidermal growth factor receptor sensitive mutation was found in 2 MTB-positive patients with lung adenocarcinoma. They received erlotinib as re-challenge regimen alongside HRE regimen in one patient and X-based regimen without rifampicin in the other. Both died because of cancer progression, 140 and 90 days after the initiation of erlotinib, respectively. Regular MTB cultures were performed for both patients every other week. Cultures were negative in each patient two and three consecutive times, respectively. None of the 30 patients enrolled in this study experienced recurrence of MTB through their clinical course.

Fig. 1 Thoracic computed tomography findings in 4 cancer patients with active *Mycobacterium tuberculosis*. a Non-small cell lung cancer patient with a thick wall cavity in the left lung with an infiltration shadow in the right upper lobe. b Colorectal cancer patient with multiple nodules in both lungs. c Breast cancer patient with a small cavity with an infiltration shadow in the right upper lobe. d Non-small cell lung cancer patient with multiple small nodules with partial patty follicular spot in the both lungs and cavity formation in the S6 segment of the right lung and lingular segment of the left lung.
Adverse events of concurrent chemotherapy

Hematological adverse events of Grade ≥3 were observed in 19 (67.9%) of 28 patients; the laboratory data for 2 patients were lost. Non-hematological adverse events of Grade ≥3 were observed in 5 (17.9%) of 28 patients.

Number of cases in concurrent chemotherapy-related adverse events are shown in Table 4. There were no significant differences in the occurrence of adverse events between different cancer types, except for lymphopenia and neutropenia. Grade 3 lymphopenia and higher were significantly more frequent in LC compared to other malignancies (P < 0.005). Grade 3 Neutropenia and higher tended to be more frequent in LC compared to other malignancies. In non-hematological adverse events, Grade 1–2 liver dysfunction was frequently observed in each malignancies.

One CRC patient experienced Grade 3 hemoptysis and another 2 experienced Grade 3 anaphylaxis (oxaliplatin-induced [n = 1] and cetuximab-induced [n = 1]). One patient with CCA and GC experienced Grade 3 pseudomembranous colitis as a result of a *Clostridium difficile* infection. One LC patient died of pemetrexed-induced pneumonitis (Grade 5).

**Overall survival**

The median OS in all patients was 10.5 (8.7–36.7; 95.0% confidence interval) months (Fig. 2a). The median OS according to the type of malignancy were 8.7 (4.7–10.0), 36.7 (minimum 2.2), and 14.4 (minimum 9.6) months for LC, CRC, and other malignancies, respectively (Fig. 2b).

**Discussion**

This study demonstrates the efficacy and safety of concurrent anti-CCT and anti-MTB chemotherapy for cancer patients with active *MTB*, confirming the findings of our previous preliminary study [2] in a bigger sample size with a variety of cancer types.

In Japan, the national rates for success, failed, died, and lost to follow-up of anti-MTB chemotherapy in 2015 were 52.8, 0.4, 17.0, and 5.6%, respectively [18]. In Nagoya which is almost similar to Osaka, where our institution is located, the rates of success, failed, died, and the others were 52.0,
The success rate of anti-MTB chemotherapy in this study may have been higher than previous studies [18, 19], possibly because of no loss to follow-up and no unevaluated patient in the present study. However, it is important that there were no MTB-related treatment failures in our study, suggesting that cancer patients with active MTB would be able to tolerate anti-MTB chemotherapy while receiving anti-CCT as well as non-cancer patients with active MTB.

Conversely, the ORRs for all patients combined, LC patients, CRC patients, and other malignancy patients were 36.7, 33.3, 40.0, and 40.0%, respectively.

In 15 LC patients, all 5 patients with SCLC received intensive cytotoxic treatment (carboplatin plus etoposide) as first line chemotherapy (Table 3) with a high response rate (80%), which is similar to the response rate (73%) of similar treatment regimen in the elderly patient or those at poor risk with extensive disease [20]. On the other hand, 10% of response rate in 10 NSCLC patients

### Table 3: Outcomes of Anti-Cancer Chemotherapy (Anti-CCT) and Anti-MTB Chemotherapy

| Characteristic | Patients | | | |
|---------------|---------|---------|---------|---------|
|               | All (n = 30) | LC (SCLC/NSCLC) (n = 15, 5/10) | CRC (n = 10) | Other (n = 5) |
| Initial concurrent anti-CCT regimen, n | | | | |
| Intensive cytotoxic regimen and targeted agent | 4 | 0 | 3 | 1 |
| Intensive cytotoxic regimen | 19 | 10 (5/5) | 6 | 3 |
| Single targeted agent | 2 | 2 (0/2) | 0 | 0 |
| Single cytotoxic agent | 5 | 3 (0/3) | 1 | 1 |
| Best response on anti-CCT after commencing concurrent chemotherapy, n | | | | |
| CR | 1 | 0 | 1 | 0 |
| PR | 10 | 5 (4/1) | 3 | 2 |
| SD | 5 | 2 (0/2) | 3 | 0 |
| PD | 6 | 4 (0/4) | 2 | 0 |
| NE | 8 | 4 (1/3) | 1 | 3 |
| ORR (%) | 36.7 | 33.3 (80.0/10.0) | 40.0 | 40.0 |
| Main anti-MTB chemotherapy, n | | | | |
| 2HREZ/7HR | 15 | 8 (3/5) | 4 | 3 |
| 6HRE/6HR | 7 | 2 (0/2) | 4 | 1 |
| Levofloxacin-based | 8 | 5 (2/3) | 2 | 1 |
| Duration of anti-MTB treatment (days), median (range) | 275.0 (72–637) | 274.0 (90–469) | 259.0 (72–539) | 368.0 (273–637) |
| Duration of concurrent chemotherapy (days), median (range) | 157.5 (13–408) | 1170.0 (20–245) | 168.5 (13–408) | 155.0 (51–376) |
| MTB treatment outcomes, n (%) | | | | |
| Cured | 20 (66.7) | 10 (66.7) | 6 (60.0) | 4 (80.0) |
| Completed | 1 (3.3) | 0 | 1 (10.0) | 0 |
| Died | 9 (30) | 5 (33.3) | 3 (30.0) | 1 (20.0) |
| Failed | 0 | 0 | 0 | 0 |
| Not evaluated | 0 | 0 | 0 | 0 |
| Success (%) | 70.0 | 66.7 | 70.0 | 80.0 |

Abbreviations: CI confidence interval, CR complete response, CRC colorectal cancer, E ethambutol, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, H isoniazid, LC lung cancer, MTB Mycobacterium tuberculosis, NE not evaluable, ORR overall response rate, PD progressive disease, PR partial response, R rifampicin, SD stable disease, Z pyrazinamide

*Two cytotoxic agents combined with targeted therapy (bevacizumab or trastuzumab)

*Two cytotoxic agents

*Erlotinib

*Single cytotoxic agent (5-FU, vinorelbine, or pemetrexed)

*CR + PR

*Daily drug combination containing HREZ for 2 months, followed by daily HR for 7 months

*Daily drug combination containing HRE for 6 months, followed by HR for 6 months

*Cured + completed
seems to be low. This may be because 6 (60.0%) of 10 NSCLC patients had received second-line or later anti-CCT after starting anti-MTB chemotherapy.

ORR in CRC patients with MTB was 40% which was similar to other 1st line combined chemotherapy regimens without molecular targeted therapy in previous reports [21, 22].

Although there were no significant differences in patient characteristics between the LC, CRC, and other malignancy groups, the diagnosis of MTB was more frequently reached during chemotherapy in LC patients when compared to patients with other types of malignancies. If LC and pulmonary MTB coexist in the lungs, a diagnosis of MTB becomes more difficult. Therefore, MTB diagnosis tends to be delayed in these patients.

In a Japanese retrospective study, [23] 247 (28.7%) of 861 patients who received MTB treatment experienced adverse events. The frequency of adverse events with MTB treatment alone, prior to the initiation of concurrent chemotherapy, in our study was equal to that of the a previous study. [23] Besides, upon starting concurrent chemotherapy in LC and CRC, we did not expect any differences in the prevalence of adverse events between this study and previous studies [20–22] except for liver dysfunction which may be correlated with MTB treatment.

Concurrent chemotherapy-related toxicities were generally acceptable except death caused by pemetrexed-induced pneumonitis. Grade 3 lymphopenia and higher were significantly more frequent in LC compared to other malignancies. The treatment related lymphopenia may affect poor prognosis in LC patients through decreased immune system shown in previous study [24].

Increased multi-drug resistance and extensive drug resistance among strains of MTB is becoming a serious problem worldwide. Hattori et al. reported that 171

| Table 4 Concurrent Chemotherapy-Related Adverse Events |
|-----------------|-----------------|-----------------|-----------------|
|                 | (Grade)         |                 |                 |
|                 | All (n = 28)    | LC (n = 13)     | CRC (n = 10)    | Other (n = 5)   |
| Adverse event   | Grade 1–2       | ≥3              | 1–2            | ≥3              |
| Hematological   |                 |                 |                 |                 |
| toxicity, number|                 |                 |                 |                 |
| of cases        |                 |                 |                 |                 |
| Leukocytopenia  | 7               | 8               | 6              | 3              |
| Neutropenia     | 5               | 14              | 1              | 9              |
| Anemia          | 20              | 2               | 9              | 2              |
| Thrombocytopenia| 3               | 3               | 1              | 2              |
| Lymphopenia     | 13              | 10              | 4              | 3              |
| Non-hematological toxicity, number of cases | | | |
| AST/ALT elevation | 12             | 0               | 4              | 6              |
| Interstitial pneumonitis | 0            | 1               | 0              | 0              |
| Colitis         | 0               | 1               | 0              | 0              |
| Anaphylaxis     | 0               | 2               | 0              | 0              |
| Hemorrhage      | 1               | 1               | 0              | 1              |

**Abbreviations**
CRC colorectal cancer, LC lung cancer
NCI-CTC National Cancer Institute Common Toxicity Criteria
\(^a\) In two of 15 patients, laboratory data was lost
\(^b\) Death caused by pemetrexed-induced pneumonitis
\(^c\) Pseudomembranous colitis due to *Clostridium difficile* infection
\(^d\) Oxaliplatin- and cetuximab-induced anaphylaxis
\(^e\) Nasal bleeding
\(^f\) Hemoptysis
: \( P < 0.005 \)

**Fig. 2** (a) Kaplan-Meier curve of overall survival for 30 cancer patients with active *Mycobacterium tuberculosis* who received concurrent chemotherapy between January 1, 2006 and February 29, 2016. The median OS in all patients was 10.5 (8.7–36.7; 95.0% confidence interval) months (b) Kaplan-Meier curves of overall survival according to cancer type. Lung Cancer patients are represented by the thick solid line, Colorectal Cancer patients are represented by the thin solid line, and patients with Other malignancies, are represented by the dashed line. The median OS according to the type of malignancy were 8.7 (4.7–10.0), 36.7 (minimum 2.2), and 14.4 (minimum 9.6) months for Lung Cancer, Colorectal Cancer, and Other malignancies, respectively.
patients (0.2%) in Japan were diagnosed with multi-drug resistant MTB, and 48 of these (28.1%) were foreigners [25]. Although the number of multi-drug resistant MTB cases in Japan is low, Osaka city and Osaka prefecture have the highest prevalence of tuberculosis in Japan (34.4 and 18.2 per 100,000 individuals in 2015, respectively) [26]. Hence, we are exceedingly cautious of an increase in multi-drug resistant MTB. In our institution, anti-CCT was suspended as far as possible until the results of the sensitivity test were known.

Given the benefits of a short duration from MTB diagnosis to the turnaround of results from sensitivity test, MGIT [5] is recommended for culturing mycobacterial organisms.

In this study, 2 (8.0%) of 25 patients had resistant MTB to H and streptomycin and H and Z, respectively, but there was no patient with multi-drug resistant MTB. In National-wide survey in Japan [27], the frequencies of drug-resistant isolates from new cases were as follows 8.5% to any drug which was similar to this study.

Poor PS, extensively drug-resistant MTB (XDR), and severe organ dysfunction were the basic contra-indications for concurrent chemotherapy. However, targeted therapy including EGFR-TKI may be used in selected patients despite a poor PS. Furthermore, concurrent chemotherapy may be initiated in patients with rapidly progressive cancer without awaiting the results of MTB sensitivity test, even if the MTB is later categorized as XDR. Therefore, there may be no strict contra-indications for concurrent chemotherapy. However, since 6 (20%) of 30 patients experienced adverse events while receiving MTB treatment alone until concurrent chemotherapy, awaiting the result of sensitivity test will be important not only for excluding XDR but also to evaluate the adverse events of MTB treatment alone.

Concurrent use of R, which induces CYP3A4 and CYP2C8 [28, 29], may weaken the clinical efficacy of some anti-CCT agents. In clinical practice, we attempt not administer concurrent chemotherapy along with Erlotinib, Irinotecan, or Pcltixel and HRE regimen as much as possible. Therefore, a better choice would be X-based regimen or other regimens without rifampin.

The limitations of this study include its retrospective design and relatively small sample size. It remains unclear whether the findings of this study could be generalized for hematological malignancies or solid malignancies except LC and CRC, or expanded to other institutions. Therefore, a prospective multi-institutional study to evaluate the efficacy and safety of concurrent anti-CCT and anti-MTB chemotherapy in patients with various types of solid tumors and an active MTB infection is warranted.

Conclusions
Concurrent anti-CCT and anti-MTB chemotherapy is effective and safe for treating cancer patients with active MTB.

Abbreviations
Anti-CCT: Anti-cancer chemotherapy; ATS: American Thoracic Society; CC: Concurrent chemotherapy; CCA: Cholangiocellular carcinoma; CCT: Cancer chemotherapy; CI: Confidence interval; CR: Complete response; CRC: Colorectal cancer; CT: Computed tomography; E: Ethambutol; GC: Gastric cancer; H: Isoniazid; IDSA: Infectious Diseases Society of America; LAMP: Loop-mediated isothermal amplification; LC: Lung cancer; MDR-TB: Multi-drug resistant Mycobacterium Tuberculosis; MGIT: Mycobacteria Growth Indicator Tube; MST: Median survival time; MTB: Mycobacterium tuberculosis; NE: Not evaluable; NSCLC: Non-small cell lung carcinoma; PCR: Polymerase chain reaction; PD: Progressive disease; PR: Partial response; XDR: Extensively drug-resistant MTB; Z: Pyrazinamide

Acknowledgements
The authors thank Editage (www.editage.jp) for English language editing and a part donation to the Osaka Prefectural Hospital Organization (Osaka, Japan) for writing our manuscript.

Funding
This study had no funding source.

Availability of data and materials
We cannot share the detailed data, because the Institutional Review Board of the Osaka Habikino Medical Center has not approved it.

Authors' contributions
TH, HS, NO, YT, and TN planned and designed the study. TH, YT, YH, SH and TN collected data of Bacteriological Examinations, and adverse effects and outcomes of MTB treatment; TH, AT, TS, NM, HS, NO, SA, MF, YK, KS, AN, and SM collected data of adverse effects and outcomes of cancer treatment. TH and HS performed the statistical analyses. All authors have been involved in drafting the manuscript or revising it critically for important intellectual content and approved the final manuscript.

Ethics approval and consent to participate
Ethics and publication of this study was approved by the Institutional Review Board of the Osaka Habikino Medical Center (formerly the Osaka Prefectural Medical Center for Respiratory and Allergic Diseases) (Osaka, Japan) on January 30, 2017 (approval no.: 808). The board waived the requirement for informed written consent due to the anonymous nature of the data and the fact that this research presented no risk of exposure to the subjects. Research was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.

Consent for publication
Not applicable.

Competing interests
TH. has received honoraria and research funding from Ono Pharmaceutical Co. Ltd. (Osaka, Japan), Lilly Japan Co. Ltd. (Hyogo, Japan), AstraZeneca Co. Ltd. (Osaka, Japan), Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan), Chugai Pharmaceutical Co. Ltd. (Tokyo, Japan), and MSD Oncology Co. Ltd. (Tokyo, Japan). T.H. received honoraria from Kyowa-Hakko Kirin and Boehringer Ingelheim. T.H. received research funding from Merck Serono Co. Ltd. (Tokyo, Japan). The remaining authors (YT, TH, SH, AT, TS, NM, HS, NO, SA, MF, YK, KS, AN, SM, and T.N.) declare no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588, Japan. 2Departments of Clinical Laboratory, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City,
References

1. WHO. Global tuberculosis report 2017. [http://www.who.int/tb/country/data/download/en/]. Accessed 1 Aug 2018.

2. Hirashima T, Nagai T, Shigeoka H, Tamura Y, Yoshida H, Kawahara K, et al. Comparison of the clinical courses and chemotherapeutic outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansaii infection: a retrospective study. BMC Cancer. 2014;14:70.

3. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6:570–81.

4. Notomi T, Okajima H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28:E63.

5. Bemer P, Palicova F, Rusch-Gerdes S, Drugeon HB, Pfyffer GE. Multicenter evaluation of fully automated BACTEC mycobacteria growth Indicator tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2002;40:150–4.

6. Kudoh S, Kudoh T. A simple technique for culturing tubercle bacilli. Bull World Health Organ. 1974;51:71–82.

7. Yajko DM, Madej JJ, Lancaster MV, Gertler J, et al. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol. 1995;33:2324–7.

8. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American thoracic society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–62.

9. WHO. Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014) A2.1 Treatment outcomes for TB patients [http://apps.who.int/iris/bitstream/10665/9789241505345_eng.pdf]. Accessed 1 Aug 2018.

10. JLCS Guidelines 2015 for the Treatment of Lung Cancer [https://www.haigan.gr.jp/modules/guideline/]. Accessed 1 Aug 2018.

11. Watanabe T, Ibaishi M, Shimada Y, Tanaka S, Ito Y, Ajoka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–39.

12. Japanese gastric cancer treatment guidelines [http://www.jgca.jp/guideline.html]. Accessed 1 Aug 2018.

13. Tozaki M, Kuroki Y, Kikuchi M, Kojima Y, Kubota K, Nakahara H, et al. The Japanese breast cancer society clinical practice guidelines for screening and imaging diagnosis of breast cancer, 2015 edition. Breast Cancer. 2016;23:357–66.

14. Furuse J, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepato-Biliary-Pancreat Surg. 2008;15:55–62.

15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, National Cancer Institute. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.

16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.

17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

18. WHO. Download treatment outcomes [http://www.who.int/tb/country/data/download/en/]. Accessed 1 Aug 2018.